Puma Biotechnology | PBYI - Selling And Administration Expenses


Puma Biotechnology reported $16.82M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
MacroGenics USD 7.94M 1.96M Dec/2025
Moderna USD 173M 135M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026